Referências
Principais artigos
Jophlin LL, Singal AK, Bataller R, et al. ACG clinical guideline: alcohol-associated liver disease. Am J Gastroenterol. 2024 Jan 1;119(1):30-54.Texto completo Resumo
Crabb DW, Im GY, Szabo G, et al. Diagnosis and treatment of alcohol-associated liver diseases: 2019 practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2020 Jan;71(1):306-33.Texto completo Resumo
Artigos de referência
1. Jophlin LL, Singal AK, Bataller R, et al. ACG clinical guideline: alcohol-associated liver disease. Am J Gastroenterol. 2024 Jan 1;119(1):30-54.Texto completo Resumo
2. Centers for Disease Control and Prevention. Alcohol use. [internet publication].Texto completo
3. Axley PD, Richardson CT, Singal AK. Epidemiology of alcohol consumption and societal burden of alcoholism and alcoholic liver disease. Clin Liver Dis. 2019 Feb;23(1):39-50. Resumo
4. World Health Organization. Fact sheet: alcohol. Jun 2024 [internet publication].Texto completo
5. Julien J, Ayer T, Bethea ED, et al. Projected prevalence and mortality associated with alcohol-related liver disease in the USA, 2019-40: a modelling study. Lancet Public Health. 2020 Jun;5(6):e316-23.Texto completo Resumo
6. Substance Abuse and Mental Health Services Administration (SAMHSA). Results from the 2018 national survey on drug use and health. 2019 [internet publication].Texto completo
7. National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health. Alcohol facts and statistics. Jun 2024 [internet publication].Texto completo
8. Office for Health Improvement & Disparities. Liver disease profiles, July 2023 update. Jul 2023 [internet publication].Texto completo
9. Office for Health Improvement & Disparities. Liver disease: applying all our health. May 2022 [internet publication].Texto completo
10. Xu H, Xiao P, Zhang F, et al. Epidemic characteristics of alcohol-related liver disease in Asia from 2000 to 2020: a systematic review and meta-analysis. Liver Int. 2022 Aug;42(9):1991-98.Texto completo Resumo
11. Thursz M, Lingford-Hughes A. Advances in the understanding and management of alcohol-related liver disease. BMJ. 2023 Nov 20;383:e077090.Texto completo Resumo
12. National Institute for Health and Care Excellence. Cirrhosis in over 16s: assessment and management. Sep 2023 [internet publication].Texto completo
13. Rehm J, Taylor B, Mohapatra S, et al. Alcohol as a risk factor for liver cirrhosis: a systematic review and meta-analysis. Drug Alcohol Rev. 2010 Jul;29(4):437-45. Resumo
14. Gao B, Bataller R. Alcoholic liver disease: pathogenesis and new therapeutic targets. Gastroenterology. 2011 Nov;141(5):1572-85.Texto completo Resumo
15. Singal AK, Mathurin P. Diagnosis and treatment of alcohol-associated liver disease: a review. JAMA. 2021 Jul 13;326(2):165-76. Resumo
16. Mueller S, Millonig G, Seitz HK. Alcoholic liver disease and hepatitis C: a frequently underestimated combination. World J Gastroenterol. 2009 Jul 28;15(28):3462-71.Texto completo Resumo
17. Chiang DJ, McCullough AJ. The impact of obesity and metabolic syndrome on alcoholic liver disease. Clin Liver Dis. 2014 Feb;18(1):157-63.Texto completo Resumo
18. Raynard B, Balian A, Fallik D, et al. Risk factors of fibrosis in alcohol-induced liver disease. Hepatology. 2002 Mar;35(3):635-8.Texto completo Resumo
19. Hart CL, Morrison DS, Batty GD, et al. Effect of body mass index and alcohol consumption on liver disease: analysis of data from two prospective cohort studies. BMJ. 2010 Mar 11;340:c1240.Texto completo Resumo
20. Klatsky AL, Armstrong MA. Alcohol, smoking, coffee, and cirrhosis. Am J Epidemiol. 1992 Nov 15;136(10):1248-57. Resumo
21. Morgan TR, Mandayam S, Jamal MM. Alcohol and hepatocellular carcinoma. Gastroenterology. 2004 Nov;127(5 Suppl 1):S87-96. Resumo
22. Zhao YY, Xiao M, Zhang CL, et al. Associations between the tumor necrosis factor-α gene and interleukin-10 gene polymorphisms and risk of alcoholic liver disease: A meta-analysis. Clin Res Hepatol Gastroenterol. 2016 Sep;40(4):428-39. Resumo
23. Wang X, Yan Z, Ye Q. Interleukin-6 gene polymorphisms and susceptibility to liver diseases: A meta-analysis. Medicine (Baltimore). 2019 Dec;98(50):e18408.Texto completo Resumo
24. Salameh H, Raff E, Erwin A, et al. PNPLA3 gene polymorphism is associated with predisposition to and severity of alcoholic liver disease. Am J Gastroenterol. 2015 Jun;110(6):846-56. Resumo
25. Stickel F, Datz C, Hampe J, et al. Pathophysiology and management of alcoholic liver disease: update 2016. Gut Liver. 2017 Mar 15;11(2):173-88.Texto completo Resumo
26. Gramenzi A, Caputo F, Biselli M, et al. Review article: alcoholic liver disease - pathophysiological aspects and risk factors. Aliment Pharmacol Ther. 2006 Oct 15;24(8):1151-61.Texto completo Resumo
27. Rao R. Endotoxemia and gut barrier dysfunction in alcoholic liver disease. Hepatology. 2009 Aug;50(2):638-44.Texto completo Resumo
28. Li Y, Zhou J. Roles of silent information regulator 1-serine/arginine-rich splicing factor 10-lipin 1 axis in the pathogenesis of alcohol fatty liver disease. Exp Biol Med (Maywood). 2017 Jun;242(11):1117-25. Resumo
29. Zhang R, Tang Z, Xu W, et al. Risk factors and protective factors for alcohol-related liver disease: a systematic review and meta-analysis. Alcohol Clin Exp Res. 2022 Dec;46(12):2128-36. Resumo
30. Mendenhall CL, Seeff L, Diehl AM, et al. Antibodies to hepatitis B virus and hepatitis C virus in alcoholic hepatitis and cirrhosis: their prevalence and clinical relevance. Hepatology. 1991 Oct;14(4 Pt 1):581-9. Resumo
31. Caldwell SH, Li X, Rourk RM, et al. Hepatitis C infection by polymerase chain reaction in alcoholics: false-positive ELISA results and the influence of infection on a clinical prognostic score. Am J Gastroenterol. 1993 Jul;88(7):1016-21. Resumo
32. Loft S, Olesen KL, Dossing M. Increased susceptibility to liver disease in relation to alcohol consumption in women. Scand J Gastroenterol. 1987 Dec;22(10):1251-6. Resumo
33. National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health. Women and alcohol. Jun 2019 [internet publication].Texto completo
34. Seitz HK, Stickel F. Alcoholic liver disease in the elderly. Clin Geriatr Med. 2007 Nov;23(4):905-21. Resumo
35. Anouti A, Seif El Dahan K, Rich NE, et al. Racial and ethnic disparities in alcohol-associated liver disease in the United States: A systematic review and meta-analysis. Hepatol Commun. 2024 Apr 1;8(4):e0409.Texto completo Resumo
36. Singal AK, Arsalan A, Dunn W, et al. Alcohol-associated liver disease in the United States is associated with severe forms of disease among young, females and Hispanics. Aliment Pharmacol Ther. 2021 Aug;54(4):451-61. Resumo
37. Crabb DW, Im GY, Szabo G, et al. Diagnosis and treatment of alcohol-associated liver diseases: 2019 practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2020 Jan;71(1):306-33.Texto completo Resumo
38. Buchsbaum DG, Buchanan RG, Centor RM, et al. Screening for alcohol abuse using CAGE scores and likelihood ratios. Ann Intern Med. 1991 Nov 15;115(10):774-7. Resumo
39. Girela E, Villanueva E, Hernandez-Cueto C, et al. Comparison of the CAGE questionnaire versus some biochemical markers in the diagnosis of alcoholism. Alcohol Alcohol. 1994 May;29(3):337-43. Resumo
40. Aalto M, Alho H, Halme JT, et al. AUDIT and its abbreviated versions in detecting heavy and binge drinking in a general population survey. Drug Alcohol Depend. 2009 Jul 1;103(1-2):25-9. Resumo
41. European Association for the Study of the Liver. EASL clinical practice guidelines: management of alcohol-related liver disease. J Hepatol. 2018 Jul;69(1):154-81.Texto completo Resumo
42. Senousy BE, Draganov PV. Evaluation and management of patients with refractory ascites. World J Gastroenterol. 2009 Jan 7;15(1):67-80.Texto completo Resumo
43. Ahmed Z, Ahmed U, Walayat S, et al. Liver function tests in identifying patients with liver disease. Clin Exp Gastroenterol. 2018;11:301-7.Texto completo Resumo
44. Cohen JA, Kaplan MM. The SGOT/SGPT ratio - an indicator of alcoholic liver disease. Dig Dis Sci. 1979 Nov;24(11):835-8. Resumo
45. Kwo PY, Cohen SM, Lim JK. ACG clinical guideline: evaluation of abnormal liver chemistries. Am J Gastroenterol. 2017 Jan;112(1):18-35.Texto completo Resumo
46. Koperdanova M, Cullis JO. Interpreting raised serum ferritin levels. BMJ. 2015 Aug 3;351:h3692. Resumo
47. Jarvis M, Williams J, Hurford M, et al. Appropriate use of drug testing in clinical addiction medicine. J Addict Med. 2017 May/Jun;11(3):163-73.Texto completo Resumo
48. Andresen-Streichert H, Beres Y, Weinmann W, et al. Improved detection of alcohol consumption using the novel marker phosphatidylethanol in the transplant setting: results of a prospective study. Transpl Int. 2017 Jun;30(6):611-20.Texto completo Resumo
49. Yersin B, Nicolet JF, Dercrey H, et al. Screening for excessive alcohol drinking: comparative value of carbohydrate-deficient transferrin, gamma-glutamyltransferase, and mean corpuscular volume. Arch Intern Med. 1995 Sep 25;155(17):1907-11. Resumo
50. Stauber RE, Stepan V, Trauner M, et al. Evaluation of carbohydrate-deficient transferrin for detection of alcohol abuse in patients with liver dysfunction. Alcohol Alcohol. 1995 Mar;30(2):171-6. Resumo
51. Arnts J, Vanlerberghe BTK, Roozen S, et al. Diagnostic accuracy of biomarkers of alcohol use in patients with liver disease: a systematic review. Alcohol Clin Exp Res. 2021 Jan;45(1):25-37.Texto completo Resumo
52. Lumeng L. New diagnostic markers of alcohol abuse. Hepatology. 1986 Jul-Aug;6(4):742-5. Resumo
53. Maheshwari S, Gu CN, Caserta MP, et al. Imaging of alcohol-associated liver disease. AJR Am J Roentgenol. 2024 Jan;222(1):e2329917.Texto completo Resumo
54. Moreno C, Mueller S, Szabo G. Non-invasive diagnosis and biomarkers in alcohol-related liver disease. J Hepatol. 2019 Feb;70(2):273-83.Texto completo Resumo
55. Hinkson A, Lally H, Gibson H, et al. Meta-analysis: enhanced liver fibrosis test to identify hepatic fibrosis in chronic liver diseases. Aliment Pharmacol Ther. 2023 Apr;57(7):750-62. Resumo
56. American College of Radiology. ACR Appropriateness Criteria®: abnormal liver function tests. 2023 [internet publication].Texto completo
57. Pavlov CS, Casazza G, Nikolova D, et al. Transient elastography for diagnosis of stages of hepatic fibrosis and cirrhosis in people with alcoholic liver disease. Cochrane Database Syst Rev. 2015 Jan 22;1:CD010542.Texto completo Resumo
58. Giuffrè M, Campigotto M, Colombo A, et al. The role of elastography in alcoholic liver disease: fibrosis staging and confounding factors, a review of the current literature. Minerva Gastroenterol (Torino). 2021 Jun;67(2):112-21. Resumo
59. European Association for the Study of the Liver. EASL clinical practice guidelines on non-invasive tests for evaluation of liver disease severity and prognosis - 2021 update. J Hepatol. 2021 Sep;75(3):659-89.Texto completo Resumo
60. Sterling RK, Duarte-Rojo A, Patel K, et al. AASLD Practice Guideline on imaging-based noninvasive liver disease assessment of hepatic fibrosis and steatosis. Hepatology. 2024 Mar 15 [Epub ahead of print].Texto completo Resumo
61. Louvet A, Trabut JB, Moreno C, et al. Management of alcohol-related liver disease: the French Association for the Study of the Liver and the French Alcohol Society clinical guidelines. Liver Int. 2022 Jun;42(6):1330-43.Texto completo Resumo
62. Van Ness MM, Diehl AM. Is liver biopsy useful in the evaluation of patients with chronically elevated liver enzymes? Ann Intern Med. 1989 Sep 15;111(6):473-8. Resumo
63. Mathurin P, Duchatelle V, Ramond MJ, et al. Survival and prognostic factors in patients with severe alcoholic hepatitis treated with prednisolone. Gastroenterology. 1996 Jun;110(6):1847-53. Resumo
64. Tsiaousi ET, Hatzitolios AI, Trygonis SK, et al. Malnutrition in end stage liver disease: recommendations and nutritional support. J Gastroenterol Hepatol. 2008 Apr;23(4):527-33.Texto completo Resumo
65. Sinclair M, Gow PJ, Grossmann M, et al. Review article: sarcopenia in cirrhosis--aetiology, implications and potential therapeutic interventions. Aliment Pharmacol Ther. 2016 Apr;43(7):765-77.Texto completo Resumo
66. Kośnik A, Wójcicki M. Fatigue in chronic liver disease patients: prevalence, pathophysiology, and management. Prz Gastroenterol. 2022;17(1):21-7.Texto completo Resumo
67. Shawcross DL, Dunk AA, Jalan R, et al. How to diagnose and manage hepatic encephalopathy: a consensus statement on roles and responsibilities beyond the liver specialist. Eur J Gastroenterol Hepatol. 2016 Feb;28(2):146-52.Texto completo Resumo
68. Sansone A, Romanelli F, Sansone M, et al. Gynecomastia and hormones. Endocrine. 2017 Jan;55(1):37-44. Resumo
69. Bell H, Tallaksen CM, Try K, et al. Carbohydrate-deficient transferrin and other markers of high alcohol consumption: a study of 502 patients admitted consecutively to a medical department. Alcohol Clin Exp Res. 1994 Oct;18(5):1103-8. Resumo
70. Prati D, Taioli E, Zanella A, et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med. 2002 Jul 2;137(1):1-10. Resumo
71. Marsano LS, Mendez C, Hill D, et al. Diagnosis and treatment of alcoholic liver disease and its complications. Alcohol Res Health. 2003;27(3):247-56.Texto completo Resumo
72. Singal A, Volk ML, Waljee A, et al. Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis. Aliment Pharmacol Ther. 2009 Jul;30(1):37-47. Resumo
73. Stewart SH, Koch DG, Willner IR, et al. Validation of blood phosphatidylethanol as an alcohol consumption biomarker in patients with chronic liver disease. Alcohol Clin Exp Res. 2014 Jun;38(6):1706-11. Resumo
74. Vos AD, Troyer RD, Stove C, et al. Biomarkers of alcohol misuse. In: Preedy VR, ed. Neuroscience of alcohol. Cambridge, MA: Academic Press; 2019:557-65.
75. US Preventive Services Task Force., Curry SJ, Krist AH, et al. Screening and behavioral counseling interventions to reduce unhealthy alcohol use in adolescents and adults: US Preventive Services Task Force recommendation statement. JAMA. 2018 Nov 13;320(18):1899-1909.Texto completo Resumo
76. Hoeksema HL, de Bock GH. The value of laboratory tests for the screening and recognition of alcohol abuse in primary care patients. J Fam Pract. 1993 Sep;37(3):268-76. Resumo
77. Thompson Coon J, Rogers G, Hewson P, et al. Surveillance of cirrhosis for hepatocellular carcinoma: systematic review and economic analysis. Health Technol Assess. 2007 Sep;11(34):1-206.Texto completo Resumo
78. Singal AG, Llovet JM, Yarchoan M, et al. AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. Hepatology. 2023 Dec 1;78(6):1922-65.Texto completo Resumo
79. Colli A, Fraquelli M, Casazza G, et al. Accuracy of ultrasonography, spiral CT, magnetic resonance, and alpha-fetoprotein in diagnosing hepatocellular carcinoma: a systematic review. Am J Gastroenterol. 2006 Mar;101(3):513-23. Resumo
80. Berry PA, Thomson SJ, Rahman TM, et al. Review article: towards a considered and ethical approach to organ support in critically-ill patients with cirrhosis. Aliment Pharmacol Ther. 2013 Jan;37(2):174-82.Texto completo Resumo
81. Powell WJ Jr, Klatskin G. Duration of survival in patients with Laennec's cirrhosis: influence of alcohol withdrawal, and possible effects of recent changes in general management of the disease. Am J Med. 1968 Mar;44(3):406-20. Resumo
82. Lim WH, Tay P, Ng CH, et al. Meta-analysis: Prevalence and impact of alcohol abstinence in alcohol-associated cirrhosis. Aliment Pharmacol Ther. 2024 Mar;59(6):730-41.Texto completo Resumo
83. Veldt BJ, Laine F, Guillygomarc'h A, et al. Indication of liver transplantation in severe alcoholic liver cirrhosis: quantitative evaluation and optimal timing. J Hepatol. 2002 Jan;36(1):93-8. Resumo
84. Altamirano J, López-Pelayo H, Michelena J, et al. Alcohol abstinence in patients surviving an episode of alcoholic hepatitis: prediction and impact on long-term survival. Hepatology. 2017 Dec;66(6):1842-53.Texto completo Resumo
85. Naveau S, Giraud V, Borotto E, et al. Excess weight risk factor for alcoholic liver disease. Hepatology. 1997 Jan;25(1):108-11.Texto completo Resumo
86. Umemura T, Ichijo T, Matsumoto A, et al. Severe hepatic injury caused by orlistat. Am J Med. 2006 Aug;119(8):e7. Resumo
87. Sall D, Wang J, Rashkin M, et al. Orlistat-induced fulminant hepatic failure. Clin Obes. 2014 Dec;4(6):342-7. Resumo
88. Wakim-Fleming J, Mullen KD. Long-term management of alcoholic liver disease. Clin Liver Dis. 2005 Feb;9(1):135-49. Resumo
89. McCullough AJ, Tavill AS. Disordered energy and protein metabolism in liver disease. Semin Liver Dis. 1991 Nov;11(4):265-77. Resumo
90. McCullough AJ, Bugianesi E. Protein-calorie malnutrition and the etiology of cirrhosis. Am J Gastroenterol. 1997 May;92(5):734-8. Resumo
91. Vasco M, Paolillo R, Schiano C, et al. Compromised nutritional status in patients with end-stage liver disease: role of gut microbiota. Hepatobiliary Pancreat Dis Int. 2018 Aug;17(4):290-300. Resumo
92. Swart GR, Zillikens MC, van Vuure JK, et al. Effect of a late evening meal on nitrogen balance in patients with cirrhosis of the liver. BMJ. 1989 Nov 11;299(6709):1202-3.Texto completo Resumo
93. Verboeket-Van De Venne WP, Westerterp KR, Van Hoek B, et al. Habitual pattern of food intake in patients with liver disease. Clin Nutr. 1993 Oct;12(5):293-7. Resumo
94. Stickel F, Hoehn B, Schuppan D, et al. Review article: nutritional therapy in alcoholic liver disease. Aliment Pharmacol Ther. 2003 Aug 15;18(4):357-73.Texto completo Resumo
95. Muto Y, Sato S, Watanabe A, et al. Effects of oral branched-chain amino acid granules on event-free survival in patients with liver cirrhosis. Clin Gastroenterol Hepatol. 2005 Jul;3(7):705-13.Texto completo Resumo
96. Moreno C, Langlet P, Hittelet A, et al. Enteral nutrition with or without N-acetylcysteine in the treatment of severe acute alcoholic hepatitis: a randomized multicenter controlled trial. J Hepatol. 2010 Dec;53(6):1117-22. Resumo
97. Bhavsar-Burke I, Jansson-Knodell CL, Gilmore AC, et al. Review article: the role of nutrition in alcohol-associated liver disease. Aliment Pharmacol Ther. 2021 Jun;53(12):1268-76. Resumo
98. Antar R, Wong P, Ghali P. A meta-analysis of nutritional supplementation for management of hospitalized alcoholic hepatitis. Can J Gastroenterol. 2012 Jul;26(7):463-7. Resumo
99. Gluud LL, Dam G, Les I, et al. Branched-chain amino acids for people with hepatic encephalopathy. Cochrane Database Syst Rev. 2017 May 18;(5):CD001939.Texto completo Resumo
100. Koretz RL. The evidence for the use of nutritional support in liver disease. Curr Opin Gastroenterol. 2014 Mar;30(2):208-14. Resumo
101. Ney M, Vandermeer B, van Zanten SJ, et al. Meta-analysis: oral or enteral nutritional supplementation in cirrhosis. Aliment Pharmacol Ther. 2013 Apr;37(7):672-9.Texto completo Resumo
102. McCullough AJ, O'Connor JF. Alcoholic liver disease: proposed recommendations for the American College of Gastroenterology. Am J Gastroenterol. 1998 Nov;93(11):2022-36. Resumo
103. Barve A, Khan R, Marsano L, et al. Treatment of alcoholic liver disease. Ann Hepatol. 2008 Jan-Mar;7(1):5-15. Resumo
104. Shah ND, Barritt AS 4th. Nutrition as therapy in liver disease. Clin Ther. 2022 May;44(5):682-96.Texto completo Resumo
105. Louvet A, Thursz MR, Kim DJ, et al. Corticosteroids reduce risk of death within 28 days for patients with severe alcoholic hepatitis, compared with pentoxifylline or placebo: a meta-analysis of individual data from controlled trials. Gastroenterology. 2018 Aug;155(2):458-68. Resumo
106. Pavlov CS, Varganova DL, Casazza G, et al. Glucocorticosteroids for people with alcoholic hepatitis. Cochrane Database Syst Rev. 2019 Apr 9;(4):CD001511.Texto completo Resumo
107. Carithers RL Jr, Herlong HF, Diehl AM, et al. Methylprednisolone therapy in patients with severe alcoholic hepatitis: a randomized multicenter trial. Ann Intern Med. 1989 May 1;110(9):685-90. Resumo
108. Mathurin P, O'Grady J, Carithers RL, et al. Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis: meta-analysis of individual patient data. Gut. 2011 Feb;60(2):255-60. Resumo
109. Mathurin P, Abdelnour M, Ramond MJ, et al. Early change in bilirubin levels is an important prognostic factor in severe alcoholic hepatitis treated with prednisolone. Hepatology. 2003 Dec;38(6):1363-9.Texto completo Resumo
110. Louvet A, Naveau S, Abdelnour M, et al. The Lille model: a new tool for therapeutic strategy in patients with severe alcoholic hepatitis treated with steroids. Hepatology. 2007 Jun;45(6):1348-54.Texto completo Resumo
111. Imperiale TF, McCullough AJ. Do corticosteroids reduce mortality from alcoholic hepatitis? A meta-analysis of the randomized trials. Ann Intern Med. 1990 Aug 15;113(4):299-307. Resumo
112. Mathurin P. Is alcoholic hepatitis an indication for transplantation? Current management and outcomes. Liver Transpl. 2005 Nov;(11 suppl 2):S21-4.Texto completo Resumo
113. Hmoud BS, Patel K, Bataller R, et al. Corticosteroids and occurrence of and mortality from infections in severe alcoholic hepatitis: a meta-analysis of randomized trials. Liver Int. 2016 May;36(5):721-8. Resumo
114. Singh S, Murad MH, Chandar AK, et al. Comparative effectiveness of pharmacological interventions for severe alcoholic hepatitis: a systematic review and network meta-analysis. Gastroenterology. 2015 Oct;149(4):958-70.e12.Texto completo Resumo
115. Tilg H, Jalan R, Kaser A, et al. Anti-tumor necrosis factor-alpha monoclonal antibody therapy in severe alcoholic hepatitis. J Hepatol. 2003 Apr;38(4):419-25. Resumo
116. Naveau S, Chollet-Martin S, Dharancy S, et al. A double-blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis. Hepatology. 2004 May;39(5):1390-7.Texto completo Resumo
117. Biggins SW, Angeli P, Garcia-Tsao G, et al. Diagnosis, evaluation, and management of ascites, spontaneous bacterial peritonitis and hepatorenal syndrome: 2021 practice guidance by the American Association for the Study of Liver Diseases. Hepatology. 2021 Aug;74(2):1014-48.Texto completo Resumo
118. European Association for the Study of the Liver. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol. 2010 Sep;53(3):397-417.Texto completo Resumo
119. Aithal GP, Palaniyappan N, China L, et al. Guidelines on the management of ascites in cirrhosis. Gut. 2021 Jan;70(1):9-29.Texto completo Resumo
120. Biggins SW, Angeli P, Garcia-Tsao G, et al. Diagnosis, evaluation, and management of ascites, spontaneous bacterial peritonitis and hepatorenal syndrome: 2021 practice guidance by the American Association for the Study of Liver Diseases. Hepatology. 2021;74(2):1014-48.Texto completo Resumo
121. European Association for the Study of the Liver. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol. 2010;53(3):397-417.Texto completo Resumo
122. Bernardi M, Carceni P, Navickis RJ, et al. Albumin infusion in patients undergoing large-volume paracentesis: a meta-analysis of randomized trials. Hepatology. 2012 Apr;55(4):1172-81.Texto completo Resumo
123. Aithal GP, Palaniyappan N, China L, et al. Guidelines on the management of ascites in cirrhosis. Gut. 2021 Jan;70(1):9-29.Texto completo Resumo
124. Rimola A, Garcia-Tsao G, Navasa M, et al. Diagnosis, treatment and prophylaxis of spontaneous bacterial peritonitis: a consensus document. International Ascites Club. J Hepatol. 2000;32(1):142-53. Resumo
125. Arab JP, Roblero JP, Altamirano J, et al. Alcohol-related liver disease: Clinical practice guidelines by the Latin American Association for the Study of the Liver (ALEH). Ann Hepatol. 2019 May-Jun;18(3):518-35.Texto completo Resumo
126. Loomba R, Wesley R, Bain A, et al. Role of fluoroquinolones in the primary prophylaxis of spontaneous bacterial peritonitis: meta-analysis. Clin Gastroenterol Hepatol. 2009 Apr;7(4):487-93. Resumo
127. Rusu A, Munteanu AC, Arbănași EM, et al. Overview of side-effects of antibacterial fluoroquinolones: new drugs versus old drugs, a step forward in the safety profile? Pharmaceutics. 2023 Mar 1;15(3):804.Texto completo Resumo
128. Goel A, Rahim U, Nguyen LH, et al. Systematic review with meta-analysis: rifaximin for the prophylaxis of spontaneous bacterial peritonitis. Aliment Pharmacol Ther. 2017 Dec;46(11-12):1029-36.Texto completo Resumo
129. Wang W, Yang J, Liu C, et al. Norfloxacin, ciprofloxacin, trimethoprim-sulfamethoxazole, and rifaximin for the prevention of spontaneous bacterial peritonitis: a network meta-analysis. Eur J Gastroenterol Hepatol. 2019 Aug;31(8):905-10.Texto completo Resumo
130. Fernández J, Ruiz del Arbol L, Gómez C, et al. Norfloxacin vs ceftriaxone in the prophylaxis of infections in patients with advanced cirrhosis and hemorrhage. Gastroenterology. 2006 Oct;131(4):1049-56.Texto completo Resumo
131. Song S, Yang Y, Geng C, et al. Norfloxacin versus alternative antibiotics for prophylaxis of spontaneous bacteria peritonitis in cirrhosis: a systematic review and meta-analysis. BMC Infect Dis. 2023 Aug 28;23(1):557.Texto completo Resumo
132. Oshita M, Hayashi N, Kasahara A, et al. Increased serum hepatitis C virus RNA levels among alcoholic patients with chronic hepatitis C. Hepatology. 1994 Nov;20(5):1115-20. Resumo
133. Ohnishi K, Matsuo S, Matsutani K, et al. Interferon therapy for chronic hepatitis C in habitual drinkers: comparison with chronic hepatitis C in infrequent drinkers. Am J Gastroenterol. 1996 Jul;91(7):1374-9. Resumo
134. Keeffe EB. Comorbidities of alcoholic liver disease that affect outcome of orthotopic liver transplantation. Liver Transpl Surg. 1997 May;3(3):251-7. Resumo
135. Gong A, Minuk GY. Predictors of alcohol relapse following liver transplantation for alcohol-induced liver failure. consideration of "A-D" selection criteria. Ann Transplant. 2018 Feb 20;23:129-35.Texto completo Resumo
136. Obed A, Bashir A, Stern S, et al. Severe acute alcoholic hepatitis and liver transplant: a never-ending mournful story. Clin Mol Hepatol. 2018 Dec;24(4):358-66.Texto completo Resumo
137. Ramirez-Cadiz C, Blaney H, Kubanek N, et al. Review article: Current indications and selection criteria for early liver transplantation in severe alcohol-associated hepatitis. Aliment Pharmacol Ther. 2024 May;59(9):1049-61. Resumo
138. Dunn W, Jamil LH, Brown LS, et al. MELD accurately predicts mortality in patients with alcoholic hepatitis. Hepatology. 2005 Feb;41(2):353-8.Texto completo Resumo
139. Marot A, Dubois M, Trépo E, et al. Liver transplantation for alcoholic hepatitis: a systematic review with meta-analysis. PLoS One. 2018 Jan 11;13(1):e0190823.Texto completo Resumo
140. Al-Saeedi M, Barout MH, Probst P, et al. Meta-analysis of patient survival and rate of alcohol relapse in liver-transplanted patients for acute alcoholic hepatitis. Langenbecks Arch Surg. 2018 Nov;403(7):825-36. Resumo
141. Lee BP, Mehta N, Platt L, et al. Outcomes of early liver transplantation for patients with severe alcoholic hepatitis. Gastroenterology. 2018 Aug;155(2):422-30.e1.Texto completo Resumo
142. Singal AK, Bataller R, Ahn J, et al. ACG clinical guideline: alcoholic liver disease. Am J Gastroenterol. 2018 Feb;113(2):175-94.Texto completo Resumo
143. Silvey S, Patel NR, Tsai SY, et al. Higher rate of spontaneous bacterial peritonitis recurrence with secondary spontaneous bacterial peritonitis prophylaxis compared with no prophylaxis in 2 national cirrhosis cohorts. Am J Gastroenterol. 2024 Sep 4 [epub ahead of print]. Resumo
144. Facciorusso A, Papagiouvanni I, Cela M, et al. Comparative efficacy of long-term antibiotic treatments in the primary prophylaxis of spontaneous bacterial peritonitis. Liver Int. 2019 Aug;39(8):1448-58. Resumo
145. Wang Y, Ren J, Ren S. Larsucosterol: endogenous epigenetic regulator for treating chronic and acute liver diseases. Am J Physiol Endocrinol Metab. 2024 May 1;326(5):E577-87.Texto completo Resumo
146. Hassanein T, McClain CJ, Vatsalya V, et al. Safety, pharmacokinetics, and efficacy signals of larsucosterol (DUR-928) in alcohol-associated hepatitis. Am J Gastroenterol. 2024 Jan 1;119(1):107-15.Texto completo Resumo
147. ClinicalTrials.gov. A phase 2b study in subjects with alcoholic hepatitis to evaluate safety and efficacy of DUR-928 treatment (AHFIRM). Sep 2024 [internet publication].Texto completo
148. Singh V, Keisham A, Bhalla A, et al. Efficacy of granulocyte colony-stimulating factor and N-acetylcysteine therapies in patients with severe alcoholic hepatitis. Clin Gastroenterol Hepatol. 2018 Oct;16(10):1650-6.Texto completo Resumo
149. Baig M, Walayat S, Dhillon S, et al. Efficacy of granulocyte colony stimulating factor in severe alcoholic hepatitis: a systematic review and meta-Aanalysis. Cureus. 2020 Sep 15;12(9):e10474.Texto completo Resumo
150. Marot A, Singal AK, Moreno C, et al. Granulocyte colony-stimulating factor for alcoholic hepatitis: a systematic review and meta-analysis of randomised controlled trials. JHEP Rep. 2020 Oct;2(5):100139.Texto completo Resumo
151. Thompson J, Jones N, Al-Khafaji A, et al. Extracorporeal cellular therapy (ELAD) in severe alcoholic hepatitis: a multinational, prospective, controlled, randomized trial. Liver Transpl. 2018 Mar;24(3):380-93.Texto completo Resumo
152. Philips CA, Pande A, Shasthry SM, et al. Healthy donor fecal microbiota transplantation in steroid-ineligible severe alcoholic hepatitis: a pilot study. Clin Gastroenterol Hepatol. 2017 Apr;15(4):600-2. Resumo
153. Saunders JB, Latt N. Epidemiology of alcoholic liver disease. Baillieres Clin Gastroenterol. 1993 Sep;7(3):555-79. Resumo
154. Maddrey WC, Boitnott JK, Bedine MS, et al. Corticosteroid therapy of alcoholic hepatitis. Gastroenterology. 1978 Aug;75(2):193-9. Resumo
155. Ramond MJ, Poynard T, Rueff B, et al. A randomized trial of prednisolone in patients with severe alcoholic hepatitis. N Engl J Med. 1992 Feb 20;326(8):507-12.Texto completo Resumo
156. Forrest EH, Evans CD, Stewart S, et al. Analysis of factors predictive of mortality in alcoholic hepatitis and derivation and validation of the Glasgow alcoholic hepatitis score. Gut. 2005 Aug;54(8):1174-9.Texto completo Resumo
157. Bajaj JS, Saeian K, Schubert CM, et al. Minimal hepatic encephalopathy is associated with motor vehicle crashes: the reality beyond the driving test. Hepatology. 2009 Oct;50(4):1175-83. Resumo
158. Chavez-Tapia NC, Barrientos-Gutierrez T, Tellez-Avila FI, et al. Antibiotic prophylaxis for cirrhotic patients with upper gastrointestinal bleeding. Cochrane Database Syst Rev. 2010 Sep 8;(9):CD002907. Resumo
159. Garcia-Tsao G, Sanyal AJ, Grace ND, et al; Practice Guidelines Committee of American Association for Study of Liver Diseases; Practice Parameters Committee of American College of Gastroenterology. Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. Am J Gastroenterol. 2007 Sep;102(9):2086-102. Resumo
160. Villanueva C, Colomo A, Bosch A, et al. Transfusion strategies for acute upper gastrointestinal bleeding. N Engl J Med. 2013 Jan 3;368(1):11-21.Texto completo Resumo
161. Karwa R, Woodis CB. Midodrine and octreotide in treatment of cirrhosis-related hemodynamic complications. Ann Pharmacother. 2009 Apr;43(4):692-9. Resumo
162. Centers for Disease Control and Prevention. Adult immunization schedule by age: recommendations for ages 19 years or older, United States, 2025. Nov 2024 [internet publication].Texto completo
163. Speeg KV, Bay MK. Prevention and treatment of drug-induced liver disease. Gastroenterol Clin North Am. 1995 Dec;24(4):1047-64. Resumo
O uso deste conteúdo está sujeito ao nosso aviso legal